Stephanie Goshorn, MD
Family Medicine · Tucson, AZNPI 1215370309
Payments from drug & device makers
Across 274 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$664
- Lilly USA, LLC$461
- Amgen$304
- Novo Nordisk$261
- Pfizer$260
- Boehringer Ingelheim$252
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,227100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $664 |
| Lilly USA, LLC | 31 | $461 |
| Amgen | 17 | $304 |
| Novo Nordisk | 33 | $261 |
| Pfizer | 20 | $260 |
| Boehringer Ingelheim | 15 | $252 |
| Sumitomo Pharma America, Inc. | 9 | $215 |
| AstraZeneca | 15 | $206 |
| Exact Sciences | 10 | $182 |
| GSK | 10 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $155 |
| Sanofi-aventis U.S. LLC | 8 | $126 |
| Abbott | 6 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $120 |
| Astellas Pharma US Inc | 5 | $95 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| Collegium Pharmaceutical, Inc. | 3 | $61 |
| Johnson & Johnson | 4 | $54 |
| Bayer | 3 | $49 |
| Mylan Specialty L.p. | 2 | $42 |
| Boston Scientific | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Merck | 3 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Eisai Inc. | 2 | $29 |
| Novartis | 1 | $25 |
| BD | 1 | $23 |
| Organon | 1 | $22 |
| Gilead | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
How this compares
$4,227 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $127,370 |
| OzempicSemaglutide | 79 | $112,986 |
| FarxigaDapagliflozin Propanediol | 50 | $75,847 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $72,594 |
| JardianceEmpagliflozin | 41 | $61,789 |
| MounjaroTirzepatide | 49 | $57,425 |
| CreonLipase/Protease/Amylase | 18 | $39,506 |
| XareltoRivaroxaban | 20 | $30,529 |
| TrulicityDulaglutide | 18 | $30,153 |
| GemtesaVibegron | 14 | $18,050 |
| MyrbetriqMirabegron | 13 | $17,566 |
| EntrestoSacubitril/Valsartan | 16 | $17,303 |
| Repatha SureclickEvolocumab | 18 | $15,898 |
| JanuviaSitagliptin Phosphate | 13 | $13,797 |
| Repatha PushtronexEvolocumab | 14 | $12,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $260 | $127,37090 claims |
| Novo NordiskOzempic | $261 | $112,98679 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $156 | $89,364125 claims |
| Lilly USA, LLCMounjaro, Trulicity | $461 | $87,57767 claims |
| AstraZenecaFarxiga, Symbicort | $206 | $81,63067 claims |
| Boehringer IngelheimJardiance | $252 | $61,78941 claims |
| AbbVieCreon, Synthroid | $664 | $43,54469 claims |
| Johnson & JohnsonXarelto | $54 | $30,52920 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $215 | $18,05014 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $17,56613 claims |
| NovartisEntresto | $25 | $17,30316 claims |
| MerckJanuvia | $37 | $13,79713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Dena PetersenTucson$14.7M
- John McGettiganTucson$8.3M
- Kevin PoundsTucson$1.9M
- Thili KulatilakeTucson$1.8M
- Judith BrownTucson$399K
- Hannah LeslieTucson$228K
- Charles MichieliTucson$111K
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.